Asset

ENOBLITUZUMAB

MacroGenics Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (2)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT01391143phase1completed2011-07-012019-04-18MacroGenicsSafety Study of MGA271 in Refractory Cancer
NCT01918930phase1terminated2013-07-012016-10-01MacroGenicsTissue Procurement Substudy for Participants in Study CP-MGA271-01

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)